Literature DB >> 22537448

Pathogenesis and treatment of hepatitis e virus infection.

Heiner Wedemeyer1, Sven Pischke, Michael P Manns.   

Abstract

Hepatitis E has been considered to be a travel-associated, acute, self-limiting liver disease that causes fulminant hepatic failure in specific high-risk groups only. However, hepatitis E virus (HEV) infection can also be acquired in industrialized countries-HEV genotype 3 infection is a zoonosis, with pigs and rodents serving as animal reservoirs. In recent years, cases of chronic HEV infection that were associated with progressive liver disease have been described in several cohorts of immunocompromised individuals, including recipients of organ transplants. The topic of hepatitis E is therefore re-emerging and has raised the following important questions: what is the risk for HEV infection in Western countries (eg, from eating uncooked meat)? How frequently does chronic hepatitis E develop among human immunodeficiency virus-infected patients and recipients of organ transplants? What are the treatment options? What is the current status of vaccine development? What do we know about the pathogenesis of HEV infection, and why does it have a more severe course in pregnant women? This review summarizes the current knowledge on the pathogenesis and treatment of HEV infection.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537448     DOI: 10.1053/j.gastro.2012.02.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  83 in total

Review 1.  [Specific infections in organ transplantation].

Authors:  M Cornberg; B Schlevogt; J Rademacher; A Schwarz; M Sandherr; G Maschmeyer
Journal:  Internist (Berl)       Date:  2016-01       Impact factor: 0.743

Review 2.  Acute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment.

Authors:  Nassim Kamar; Sven Pischke
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

3.  Hepatitis E virus infection in a hematopoietic stem cell donor.

Authors:  C Koenecke; S Pischke; G Beutel; U Ritter; A Ganser; H Wedemeyer; M Eder
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

4.  Enhancement of interferon induction by ORF3 product of hepatitis E virus.

Authors:  Yuchen Nan; Zexu Ma; Rong Wang; Ying Yu; Harilakshmi Kannan; Brenda Fredericksen; Yan-Jin Zhang
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 5.  Development of new hepatitis E vaccines.

Authors:  Yufeng Cao; Zhenhong Bing; Shiyu Guan; Zecai Zhang; Xinping Wang
Journal:  Hum Vaccin Immunother       Date:  2018-06-18       Impact factor: 3.452

Review 6.  Hepatitis E: an old infection with new implications.

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Maria Bianchi; Gabriele Calizzani; Fabio Candura; Liviana Catalano; Blandina Farina; Monica Lanzoni; Vanessa Piccinini; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

Review 7.  Chronic hepatitis E: A brief review.

Authors:  Arvind R Murali; Vikram Kotwal; Saurabh Chawla
Journal:  World J Hepatol       Date:  2015-09-08

8.  Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study.

Authors:  Heléne Norder; Marie Karlsson; Åsa Mellgren; Jan Konar; Elisabeth Sandberg; Anders Lasson; Maria Castedal; Lars Magnius; Martin Lagging
Journal:  J Clin Microbiol       Date:  2015-12-09       Impact factor: 5.948

Review 9.  An update on the hepatitis E virus.

Authors:  Seth N Sclair; Eugene R Schiff
Journal:  Curr Gastroenterol Rep       Date:  2013-02

10.  Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus.

Authors:  Tauseef Ahmad; Saima Nasir; Taha Hussein Musa; Saif Aldeen S AlRyalat; Muhammad Khan; Jin Hui
Journal:  Hum Vaccin Immunother       Date:  2020-08-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.